Asset
PADNARSERTIB
Karyopharm Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02702492 | phase1 | terminated | 2016-06-08 | 2021-01-26 | Karyopharm Therapeutics Inc | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) |
FDA applications (0)
This company has no applications containing this asset.